ACL @ 9 NOV 2021Text me if you have any questions/comments for me.
-----
ACL
- Previous analysis was done on 6 Oct (red arrow) - Suggested waiting for HH and HL formation before plotting entry
- Since then, the stock is forming a series of HHs and HLs
- A rebound of the short-term support would create a new Highe
0.08AUD
35.90 MAUD
692.10 MAUD
117.35 M
About AUSTRALIAN CLINICAL LABS LIMITED
Sector
Industry
CEO
Melinda McGrath
Website
Headquarters
Clayton
Employees (FY)
5.12 K
Founded
2020
ISIN
AU0000148496
FIGI
BBG0107G4386
Australian Clinical Labs Ltd. engages in the provision of pathology services. It operates through the Pathology segment. The Pathology segment includes pathology/clinical laboratory services provided in Australia. The company was founded in 2015 and is headquartered in Clayton, Australia.
ACL @ 6 Oct 2021Text me if you have any questions/comments for me.
-----
ACL
- Previous video analysis was done on 30 Sep - Suggested waiting for HH and HL formation before plotting entry (see blue drawings)
- Instead, the stock continued to show weakness and is now at the 4.35 support levels
- Any strong break
ACL.ASX_Range Breakout_LongENTRY: 4.63
SL: 4.25
TP: 5.53
- ADX>20
- RSI<50,RSI<70
- Daily RS N/A
- Daily FFI +ve
- Daily MACD +ve
- Weekly RS N/A
- Weekly FFI +ve
- Weekly MACD N/A
- Breakout of range on 26 Aug 2021 with high volume.
- Retraced with lower volume until 3 Sep 2021 showing possible buyers coming in.
- Breakout
ACL @ 27 SEP 2021Text me if you have any questions/comments for me.
-----
ACL
- Previous analysis was done on 23 Sep - Suggested waiting for successful breakout of 4.60 levels accompanied with strong volume before plotting entry
- After last Friday’s gap up and quick retracement, I thought the stock would retrace
ACL @ 23 SEP 2021Text me if you have any questions/comments for me.
-----
ACL
- Previous analysis was done on 16 Sep - Suggested waiting for successful breakout of 4.60 levels before plotting entry
- Stock has been trapped in a band (moving sideways) for almost a month
- It still respects the short-term support ->
ACL @ 16 SEP 2021Text me if you have any questions/comments for me.
-----
ACL
- First time doing a written analysis on ACL
- Recently IPO-ed stock in mid-May – Has had some uptrends
- Had some obvious retracement around 4.60 levels
- Recently tested the short-term support and today, rebounded from there
- A succes
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ACL is 2.49 AUD — it has increased by 2.05% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange AUSTRALIAN CLINICAL LABS LIMITED stocks are traded under the ticker ACL.
AUSTRALIAN CLINICAL LABS LIMITED is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
ACL stock is 2.85% volatile and has beta coefficient of 0.78. Check out the list of the most volatile stocks — is AUSTRALIAN CLINICAL LABS LIMITED there?
ACL earnings for the last quarter are 0.08 AUD per share, whereas the estimation was 0.11 AUD resulting in a −26.82% surprise. The estimated earnings for the next quarter are 0.09 AUD per share. See more details about AUSTRALIAN CLINICAL LABS LIMITED earnings.
AUSTRALIAN CLINICAL LABS LIMITED revenue for the last quarter amounts to 338.28 M AUD despite the estimated figure of 349.00 M AUD. In the next quarter revenue is expected to reach 340.65 M AUD.
Yes, you can track AUSTRALIAN CLINICAL LABS LIMITED financials in yearly and quarterly reports right on TradingView.
ACL stock has risen by 3.32% compared to the previous week, the month change is a 6.04% fall, over the last year AUSTRALIAN CLINICAL LABS LIMITED has showed a 33.06% decrease.
ACL net income for the last quarter is 4.95 M AUD, while the quarter before that showed 10.48 M AUD of net income which accounts for −52.75% change. Track more AUSTRALIAN CLINICAL LABS LIMITED financial stats to get the full picture.
Today AUSTRALIAN CLINICAL LABS LIMITED has the market capitalization of 499.25 M, it has decreased by 0.82% over the last week.
AUSTRALIAN CLINICAL LABS LIMITED dividend yield was 4.07% in 2023, and payout ratio reached 78.21%. The year before the numbers were 11.55% and 59.85% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, ACL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AUSTRALIAN CLINICAL LABS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 5.12 K employees. See our rating of the largest employees — is AUSTRALIAN CLINICAL LABS LIMITED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AUSTRALIAN CLINICAL LABS LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AUSTRALIAN CLINICAL LABS LIMITED stock shows the sell signal. See more of AUSTRALIAN CLINICAL LABS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on AUSTRALIAN CLINICAL LABS LIMITED future price: according to them, ACL price has a max estimate of 3.35 AUD and a min estimate of 2.55 AUD. Read a more detailed AUSTRALIAN CLINICAL LABS LIMITED forecast: see what analysts think of AUSTRALIAN CLINICAL LABS LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AUSTRALIAN CLINICAL LABS LIMITED EBITDA is 166.60 M AUD, and current EBITDA margin is 25.84%. See more stats in AUSTRALIAN CLINICAL LABS LIMITED financial statements.